Subscribe to RSS
Please copy the URL and add it into your RSS Feed Reader.
https://www.thieme-connect.de/rss/thieme/en/10.1055-s-00035024.xml
Download PDF
Thromb Haemost 2001; 85(06): 979-985
DOI: 10.1055/s-0037-1615950
DOI: 10.1055/s-0037-1615950
Review Article
The Effect of Unfractionated vs. Low Molecular Weight Heparin on Tissue Factor Pathway Inhibitor Levels in Hospital Inpatients
Authors
Further Information
Publication History
Received
18 August 2000
Accepted after resubmission
05 February 2001
Publication Date:
12 December 2017 (online)
Summary
Although heparin is widely used as an antithrombotic agent, its multiple mechanisms of action are not fully defined. Recent work has suggested that tissue factor pathway inhibitor (TFPI) may contribute to the antithrombotic activity of heparin by inhibiting the extrinsic pathway of coagulation. We have investigated the effect of heparin on TFPI and have found that when unfractionated heparin is given by continuous intravenous infusion to hospitalized inpatients, TFPI levels increase 2.3-fold and remain high as long as heparin is continued, but return to baseline levels soon after the infusion is stopped. In contrast, therapeutic doses of the low molecular weight heparin, dalteparin, resulted in significantly less TFPI induction. Given the increasing number of studies establishing the clinical efficacy of low molecular weight heparins as antithrombotic agents, these results suggest that TFPI may not be a major contributor to the antithrombotic effect of heparin.
-
References
- 1 Bick R, Fareed J. Low Molecular Weight Heparins: Differences and Similarities in Approved Preparations in the United States. Clinical Applications Thrombosis / Hemostasis 1999; 5: S63-S6.
- 2 Weitz J. Low-Molecular-Weight Heparins. N Engl J Med 1997; 337: 688-98.
- 3 Abildgaard U, Lindahl A, Larsen M, Staalesen R, Sandset P. Heparin Anticoagulates Blood Through Antithrombin, Through Extrinsic Pathway Inhibitor (EPI), and Through an Unidentified Mechanism. Thromb Haemost 1991; 65: 951.
- 4 Krulder J, Strebus A, Meinders A, Briet E. Anticoagulant Effect of Unfractionated Heparin in Antithrombin-Depleted Plasma in Vitro. Haemostasis 1996; 26: 85-9.
- 5 Hansen J, Sandset P, Huseby K, Huseby N, Nordoy A. Depletion of Intravascular Pools of Tissue Factor Pathway Inhibitor (TFPI) During Repeated or Continuous Intravenous Infusion of Heparin in Man. Thromb Haemost 1996; 76: 703-9.
- 6 Gori A, Pepe G, Attanasio M, Falciani M, Abbate R, Prisco D, Fedi S, Giusti B, Brunelli T, Comeglio P, Gensini G, Serneri GN. Tissue Factor Reduction and Tissue Factor Pathway Inhibitor Release after Heparin Administration. Thromb Haemost 1999; 81: 589-93.
- 7 Broze G, Warren L, Novotny W, Higuchi D, Girard J, Miletich J. The Lipoprotein-Associated Coagulation Inhibitor that Inhibits the Factor VII-Tissue Factor Complex also Inhibits Factor Xa: Insight into its Possible Mechanism of Action. Blood 1988; 71: 335-43.
- 8 Lindahl A. Tissue Factor Pathway Inhibitor: From Unknown Coagulation Inhibitor to Major Antithrombotic Principle. Cardiovasc Res 1997; 33: 286-91.
- 9 Novotny W, Girard T, Miletich J, Broze G. Purification and Characterization of the Lipoprotein Associated Coagulation Inhibitor from Human Plasma. J Biol Chem 1989; 264: 18832-7.
- 10 Bajaj M, Kuppuswamy M, Saito H, Spitzer S, Bajaj S. Cultured Normal Human Hepatocytes do not Synthesize Lipoprotein-Associated Coagulation Inhibitor: Evidence that Endothelium is the Principal Site of its Synthesis. Proc Natl Acad Sci USA 1990; 87: 8868-73.
- 11 Hansen J, Olsen R, Webster P. Association of Tissue Factor Pathway Inhibitor with Human Umbilical Vein Endothelial Cells. Blood 1997; 90: 3568-78.
- 12 Lesnik P, Vonica A, Guerin M, Moreau M, Chapman M. Anticoagulant Activity of Tissue Factor Pathway Inhibitor in Human Plasma is Preferentially Associated with Dense Subspecies of LDL and HDL and with Lp(a). Arterioscler Thromb Vasc Biol 1993; 13: 1066-75.
- 13 Novotny W, Girard T, Miletich J, Broze G. Platelets Secrete a Coagulation Inhibitor Functionally and Antigenically Similar to the Lipoprotein-Associated Coagulation Inhibitor. Blood 1988; 72: 2020.
- 14 Novotny W, Brown S, Miletich J, Rader D, Broze G. Plasma Antigen Levels of the Lipoprotein-Associated Coagulation Inhibitor in Patient Samples. Blood 1991; 78: 387-93.
- 15 Sandset P, Abildgaard U, Larsen M. Heparin Induces Release of Extrinsic Coagulation Pathway Inhibitor (EPI). Thromb Res 1988; 50: 803-13.
- 16 Lindahl A, Abildgaard U, Larsen M, Aamodt L, Nordfang O, Beck T. Extrinsic Pathway Inhibitor (EPI) and the Post-Heparin Anticoagulant Effect in Tissue Thromboplastin Induced Coagulation. Thromb Res 1991; Suppl XIV 39-48.
- 17 Hoppensteadt D, Walenga J, Fasanella A, Jeske W, Fareed J. TFPI Antigen Levels in Normal Human Volunteers after Intravenous and Subcutaneous Administration of Unfractionated Heparin and a Low Molecular Weight Heparin. Thromb Res 1995; 77: 175-85.
- 18 Bara L, Bloch M, Zitoun D, Samama M, Collignon F, Frydman A, Uzan A, Bouthier J. Comparative Effects of Enoxaparin and Unfractionated Heparin in Healthy Volunteers on Prothrombin Consumption in Whole Blood During Coagulation, and Release of Tissue Factor Pathway Inhibitor. Thromb Res 1993; 69: 443-52.
- 19 Callander N, Rao L, Sandset P, Warn-Cramer B, Rapaport S. Binding Studies of Extrinsic Pathway Inhibitor (EPI) to a Cell Surface. Blood 1990; 76: 1647.
- 20 Ho G, Broze G, Schwartz A. Role of Heparin Sulfate Proteoglycans in the Uptake and Degradation of Tissue Factor Pathway Inhibitor-Coagulation Factor Xa Complexes. J Biol Chem 1997; 272: 16838-44.
- 21 Narita M, Bu G, Olins G, Higuchi D, Herz J, Broze G, Schwartz A. Two Receptor Systems Are Involved in the Plasma Clearance of Tissue Factor Pathway Inhibitor In Vivo. J Biol Chem 1995; 270: 24800-4.
- 22 Hansen J, Sandset P, Huseby K, Huseby N, Bendz B, Ostergaard P, Nordoy A. Differential Effect of Unfractionated Heparin and Low Molecular Weight Heparin on Intravascular Tissue Factor Pathway Inhibitor: Evidence for a Difference in Antithrombotic Action. Br J Haematol 1998; 101: 638-46.
- 23 Hansen J, Sandset P. Differential Effects of Low Molecular Weight Heparin and Unfractionated Heparin on Circulating Levels of Antithrombin and Tissue Factor Pathway Inhibitor (TFPI): A Possible Mechanism for Difference in Therapeutic Efficacy. Thromb Res 1998; 91: 177-81.
- 24 Bendz B, Hansen J, Andersen T, Ostergaard P, Sandset P. Partial Depletion of Tissue Factor Pathway Inhibitor during Subcutaneous Administration of Unfractionated Heparin, but not with Two Low Molecular Weight Heparins. Br J Haematol 1999; 107: 756-62.
- 25 Theroux P, Waters D, Lam J, Juneau M, McCans J. Reactivation of Unstable Angina after the Discontinuation of Heparin. N Engl J Med 1992; 327: 141-5.
- 26 Gold H, Torres F, Garabedian H, Werner W, Jang I, Khan A, Hagstrom J, Yasuda T, Leinbach R, Newell J, Bovill E, Stump D, Collen D. Evidence for a Rebound Coagulation Phenomenon after Cessation of a 4-Hour Infusion of a Specific Thrombin Inhibitor in Patients with Unstable Angina Pectoris. J Am Coll Cardiol 1993; 21: 1039-47.
- 27 Smith A, Holt R, Fitzpatrick K, Palacios I, Gold H, Werner W, Bovill E, Fuster V, Jang I. Transient Thrombotic State after Abrupt Discontinuation of Heparin in Percutaneous Coronary Angioplasty. Am Heart J 1996; 131: 434-9.
- 28 Bregengard C, Nordfang O, Ostergaard P, Petersen JGL, Meyn G, Diness V, Svendsen O, Hedner U. Pharmacokinetics of Full Length and Two-Domain Tissue Factor Pathway Inhibitor in Combination with Heparin in Rabbits. Thromb Haemost 1993; 70: 454-7.
- 29 Valentin S, Larnkjoer A, Ostergaard P, Nielsen J, Nordfang O. Characterization of the Binding Between Tissue Factor Pathway Inhibitor and Glycosaminoglycans. Thromb Res 1994; 75: 173-83.
- 30 Wun T. Lipoprotein-Associated Coagulation Inhibitor (LACI) is a Cofactor for Heparin: Synergistic Anticoagulant Action Between LACI and Sulfated Polysaccharides. Blood 1992; 79: 430-8.
- 31 Lupu C, Poulsen E, Roquefeuil S, Westmuckett A, Kakka V, Lupu F. Cellular Effects of Heparin on the Production and Release of Tissue Factor Pathway Inhibitor in Human Endothelial Cells in Culture. Arterioscler Thromb Vasc Biol 1999; 19: 2251-62.
- 32 Ariens R, Alberio G, Moia M, Mannucci P. Low Levels of Heparin-Releasable Tissue Factor Pathway Inhibitor in Young Patients with Thrombosis. Thromb Haemost 1999; 81: 203-7.
- 33 Maaoui A, Conard J, Horellou M, Samama M. Tissue Factor Pathway Inhibitor (TFPI) During Prolonged Treatments by Unfractionated Heparin or Low Molecular Weight Heparin. Thromb Haemost 1993; 69: 681.
- 34 Andrassy K, Eschenfelder V. Are the Pharmacokinetic Parameters of Low Molecular Weight Heparins Predictive of their Clinical Efficacy?. Thromb Res 1996; 81: S29-S38.
- 35 Huang Z, Wun T, Broze G. Kinetics of Factor Xa Inhibition by Tissue Factor Pathway Inhibitor. J Biol Chem 1993; 268: 26950-5.
- 36 Fareed J, Jeske W, Eschenfelder V, Iqbal O, Hoppensteadt D, Ahsan A. Preclinical Studies on a LMW Heparin. Thromb Res 1996; 81: S1-S27.
- 37 Simonneau G, Sors H, Charbonnier B, Page Y, Laaban J, Azarian R, Laurent M, Hirsch J, Ferrari E, Bosson J, Mottier D, Beau B. A comparison of low-molecular-weight heparin with unfractionated heparin for acute pulmonary embolism. N Engl J Med 1997; 337: 663-9.
- 38 Levine M, Gent M, Hirsh J, Leclerc J, Anderson D, Weitz J, Ginsberg J, Turpie A, Demers C, Kovacs M, Geerts W, Kassis J, Desjardins L, Cusson J, Cruickshank M, Powers P, Brien W, Haley S, Willan A. A comparison of low-molecular-weight heparin administered primarily at home with unfractionated heparin administered in the hospital for proximal deep vein thrombosis. N Engl J Med 1996; 334: 677-81.
- 39 Koopman M, Prandoni P, Piovella F, Ockelford P, Brandjes D, Meer JVD, Gallus A, Simonneau G, Chesterman C, Prins M, Bossuyt P, DeHaes H, Belt AVD, Sagnard L, D’Azemar P, Bueller H. Treatment of Venous Thrombosis with Intravenous Unfractionated Heparin Administered in the Hospital as Compared with Subcutaneous Low-Molecular-Weight Heparin Administered at Home. N Engl J Med 1996; 334: 682-7.